Dopamine receptors and the dopamine hypothesis of schizophrenia - PubMed (original) (raw)
Review
Dopamine receptors and the dopamine hypothesis of schizophrenia
P Seeman. Synapse. 1987.
Abstract
The discovery of neuroleptic drugs in 1952 provided a new strategy for seeking a biological basis of schizophrenia. This entailed a search for a primary site of neuroleptic action. The Parkinsonian effects caused by neuroleptics suggested that dopamine transmission may be disrupted by these drugs. In 1963 it was proposed that neuroleptics blocked "monoamine receptors" or impeded the release of monoamine metabolites. The neuroleptic concentration in plasma water or cerebrospinal fluid was of the order of 2 nM for haloperidol in clinical therapy. A systematic research was made between 1963 and 1974 for a primary site of neuroleptic action which would be sensitive to 2 nM haloperidol and stereoselective for (+)-butaclamol. Direct evidence that neuroleptics selectively blocked dopamine receptors occurred in 1974 with the finding that nanomolar concentrations of these drugs stereoselectively inhibited the binding of [3H]-dopamine or [3H]-haloperidol. These binding sites, now termed D2 dopamine receptors (which inhibit adenylate cyclase), are blocked by neuroleptics in direct relation to the antipsychotic potencies of the neuroleptics. No such correlation exists for D1 receptors (which stimulate adenylate cyclase). Based on the fact that dopamine-mimetic drugs elicited hallucinations, and that neuroleptics caused rigidity, Van Rossum in 1966 had suggested a hypothesis that dopamine pathways may be overactive in schizophrenia. The D2-selective blockade by all neuroleptics (except the monoamine-depleting reserpine) provided strong support for the dopamine hypothesis. Further support now comes from postmortem data and in vivo positron tomographic data, both of which indicate that the density of D2 receptors are elevated in the schizophrenic brain. The postmortem data indicate a bimodal pattern with half the schizophrenics having striatal D2 densities of 14 pmol/g (control is 13 pmol/g) and the other half having 26 pmol/g. Current positron tomographic data indicate D2 densities of 14 pmol/g in control subjects, but values of 34 pmol/g in drug-naive schizophrenics. Future tests of the dopamine hypothesis of schizophrenia may entail an examination of the amino acid composition and genes for D2 receptors in schizophrenic tissue, an examination of the ability of the D2 receptor to become phosphorylated and to desensitize into the low-affinity state, and an examination of the interaction of D2 receptors with D1 receptors or other neurotransmitters.
Similar articles
- Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A. Fink-Jensen A. Dan Med Bull. 2000 Jun;47(3):151-67. Dan Med Bull. 2000. PMID: 10913983 Review. - Brain dopamine receptors in schizophrenia and tardive dyskinesia.
Seeman P. Seeman P. Psychopharmacology Suppl. 1985;2:1-8. Psychopharmacology Suppl. 1985. PMID: 3159008 - Dopamine D4 receptors elevated in schizophrenia.
Seeman P, Guan HC, Van Tol HH. Seeman P, et al. Nature. 1993 Sep 30;365(6445):441-5. doi: 10.1038/365441a0. Nature. 1993. PMID: 8413587 - Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
Wiesel FA. Wiesel FA. Br J Psychiatry Suppl. 1994 Apr;(23):65-70. Br J Psychiatry Suppl. 1994. PMID: 7913610 Review. - Abnormal neuroleptic/dopamine receptors in schizophrenia.
Lee T, Seeman P. Lee T, et al. Adv Biochem Psychopharmacol. 1980;21:435-42. Adv Biochem Psychopharmacol. 1980. PMID: 6103653
Cited by
- Ventrolateral prefrontal cortex in macaques guides decisions in different learning contexts.
Fujimoto A, Elorette C, Fujimoto SH, Fleysher L, Russ BE, Rudebeck PH. Fujimoto A, et al. bioRxiv [Preprint]. 2024 Sep 19:2024.09.18.613767. doi: 10.1101/2024.09.18.613767. bioRxiv. 2024. PMID: 39345480 Free PMC article. Preprint. - A dopaminergic basis of behavioral control.
Ballard IC, Furman DJ, Berry AS, White RL 3rd, Jagust WJ, Kayser AS, D'Esposito M. Ballard IC, et al. bioRxiv [Preprint]. 2024 Oct 2:2024.09.17.613524. doi: 10.1101/2024.09.17.613524. bioRxiv. 2024. PMID: 39345422 Free PMC article. Preprint. - HINT1 Gene Polymorphisms, Smoking Behaviour, and Personality Traits: A Haplotype Case-Control Study.
Suchanecka A, Boroń A, Chmielowiec K, Strońska-Pluta A, Masiak J, Lachowicz M, Chmielowiec J, Trybek G, Grzywacz A. Suchanecka A, et al. Int J Mol Sci. 2024 Jul 12;25(14):7657. doi: 10.3390/ijms25147657. Int J Mol Sci. 2024. PMID: 39062900 Free PMC article. - Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis.
Sorkhou M, Singla DR, Castle DJ, George TP. Sorkhou M, et al. Addiction. 2024 Mar;119(3):411-437. doi: 10.1111/add.16370. Epub 2023 Nov 15. Addiction. 2024. PMID: 37968824 Review. - Exploring QSAR models for activity-cliff prediction.
Dablander M, Hanser T, Lambiotte R, Morris GM. Dablander M, et al. J Cheminform. 2023 Apr 17;15(1):47. doi: 10.1186/s13321-023-00708-w. J Cheminform. 2023. PMID: 37069675 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical